Key Points
- COO Mark Hollywood sold 6,120 shares on Jan. 12 at an average price of $22.67 for about $138,740, reducing his holding by 4.4% to 132,913 shares, according to an SEC filing.
- Multiple insiders (including the CEO, COO, EVP and a director) sold a combined ~55,400 shares — roughly $1.25M — on Jan. 12, a concentration of insider selling that may pressure sentiment.
- Analysts remain broadly positive with a consensus "Buy" rating and a target of $32.82, citing Phase‑3 HERIZON‑GEA‑01 results and up to $440M in potential milestone payments as key upside catalysts despite recent negative earnings metrics.
Zymeworks Inc. (NYSE:ZYME - Get Free Report) COO Mark Hollywood sold 6,120 shares of the business's stock in a transaction on Monday, January 12th. The shares were sold at an average price of $22.67, for a total value of $138,740.40. Following the sale, the chief operating officer owned 132,913 shares in the company, valued at approximately $3,013,137.71. The trade was a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Zymeworks Stock Performance
Shares of ZYME opened at $23.92 on Wednesday. Zymeworks Inc. has a 52-week low of $9.03 and a 52-week high of $28.49. The stock's 50-day simple moving average is $24.43 and its 200 day simple moving average is $18.50. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -15.95 and a beta of 1.30.
Zymeworks (NYSE:ZYME - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.02. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%.The firm had revenue of $27.61 million for the quarter, compared to analysts' expectations of $33.69 million. During the same period in the prior year, the business posted ($0.39) earnings per share. The company's revenue was up 72.6% on a year-over-year basis. On average, research analysts forecast that Zymeworks Inc. will post -1.39 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on ZYME. JMP Securities set a $32.00 price target on shares of Zymeworks in a research report on Wednesday, December 3rd. Leerink Partners set a $37.00 target price on Zymeworks in a research report on Monday, November 17th. Citigroup started coverage on Zymeworks in a report on Wednesday, December 3rd. They issued an "outperform" rating on the stock. HC Wainwright lifted their price target on Zymeworks from $26.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, November 18th. Finally, Wells Fargo & Company upgraded shares of Zymeworks from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $25.00 to $33.00 in a research report on Friday, December 12th. Eleven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $32.82.
View Our Latest Stock Analysis on Zymeworks
Zymeworks News Summary
Here are the key news stories impacting Zymeworks this week:
- Positive Sentiment: Phase‑3 HERIZON‑GEA‑01 results for Ziihera showed >2 years median overall survival in HER2‑positive GEA and consistent efficacy across PD‑L1 subgroups, with manageable safety. Zymeworks stands to earn up to $440M in milestone payments on approvals — a material revenue upside versus recent quarterly revenue (~$27.6M). This is the primary bullish catalyst supporting the stock move. HERIZON‑GEA‑01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth
- Neutral Sentiment: Zymeworks announced leadership appointments, promotions and transitions to align with its November corporate strategy — intended to sharpen execution as the company moves from development to potential commercialization. Leadership changes can be positive long term but often create short-term uncertainty. Zymeworks Announces Leadership Appointments and Transitions
- Negative Sentiment: Substantial insider selling occurred on Jan 12: CEO Kenneth Galbraith sold 30,424 shares (~11.8% of his holding), COO Mark Hollywood sold 6,120 shares, EVP Jeffrey Smith sold 9,310 shares, and director/insider Paul A. Moore sold 9,560 shares. Combined, ~55,400 shares were sold for roughly $1.25M at an average price of $22.67. Large, concentrated insider sales can weigh on sentiment and are being closely watched by investors. (CEO filing) CEO SEC Filing (EVP insider alert) Insider Selling: Zymeworks EVP Sells 9,310 Shares
Hedge Funds Weigh In On Zymeworks
Hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC increased its position in shares of Zymeworks by 86.0% during the 1st quarter. AQR Capital Management LLC now owns 48,485 shares of the company's stock valued at $577,000 after purchasing an additional 22,411 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Zymeworks by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company's stock valued at $386,000 after acquiring an additional 1,427 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Zymeworks by 184.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,879,945 shares of the company's stock valued at $46,210,000 after acquiring an additional 2,514,834 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Zymeworks by 487.0% during the first quarter. Jane Street Group LLC now owns 135,763 shares of the company's stock worth $1,617,000 after acquiring an additional 112,636 shares in the last quarter. Finally, CWM LLC lifted its holdings in shares of Zymeworks by 272.8% in the 2nd quarter. CWM LLC now owns 8,570 shares of the company's stock worth $108,000 after acquiring an additional 6,271 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.
About Zymeworks
(
Get Free Report)
Zymeworks Inc is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, with a focus on the discovery, development and commercialization of multifunctional biotherapeutics. Founded in 2003, the company applies proprietary protein engineering platforms to create novel antibody and protein-based therapies targeting oncology and other serious diseases. Zymeworks is publicly traded on the New York Stock Exchange under the symbol ZYME.
The company's core technology platforms include Azymetric®, which enables the design of bispecific antibodies capable of engaging two distinct targets simultaneously, and the EFECT™ platform for fine-tuning antibody-drug conjugate properties.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
